Disease Indications Articles
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.
Boehringer Ingelheim’s Jascayd (nerandomilast) has been given an expanded label by the U.S. Food and Drug Administration to include use in adults with progressive pulmonary fibrosis.
FDA has approved CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab), as a subcutaneous formulation, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The Centers for Disease Control and Prevention has approved a change to the nation’s childhood immunization schedule to drop the long-standing practice of giving all newborns a hepatitis B vaccine within 24 hours of birth.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.
A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.
A retrospective cohort study has found respiratory syncytial virus infections are associated with substantial morbidity among patients with systemic autoimmune rheumatic diseases, with more than half of infected individuals requiring hospitalization.
The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
A small study of medical records unexpectedly found that 12 percent of chronic pain patients who were treated with spinal cord stimulation or an implanted pain medicine pump had a white blood cell condition called eosinophilia.
Researchers at La Jolla Institute for Immunology and Columbia University Irving Medical Center have discovered that amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, may be an autoimmune disorder.
The U.S. Food and Drug Administration has granted fast track designation for Greenwich LifeSciences’ lead immunotherapy candidate GLSI-100 in HLA-A*02–positive, HER2-positive breast cancer patients who have completed standard HER2-targeted therapy.
A recent study showed treatment with intravenous immune globulin following infection from BCMA therapies yielded a 67 percent decrease in infections in patients with multiple myeloma.